Patients with a rare and incurable brain cancer could be given precious extra time after the first targeted treatment for the disease in 20 years was added to the national discounted medicines scheme.
Vorasidenib, known by the brand name Voranigo, is one of several medicines approved in August for subsidised access on the Pharmaceutical Benefits Scheme.